Email: cspc@cspc.cn
News
June 05, 2025
Share:
Previous: VOLUNTARY ANNOUNCEMENT - SYS6040 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Next: JMT101 GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR THE TREATMENT OF COLORECTAL CANCER
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us